Immune booster before chemo shows promise for tough breast cancers
NCT ID NCT02957968
First seen May 08, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can increase immune cell activity in breast tumors. It involves 46 people with locally advanced HER2-negative breast cancer, divided by hormone receptor status. The goal is to see if this approach makes the cancer more responsive to subsequent chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
-
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.